Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a prospectus with the SEC under Rule 424(b)(3) for the resale of 492,000 ordinary shares represented by 1,230 American Depositary Shares (ADSs). These shares are related to warrants issued during private placements in October 2019 and May 2020, as well as placement agent warrants connected to these placements. The selling shareholders identified in the prospectus may sell the shares at market prices or negotiated transactions. Biodexa Pharmaceuticals will not receive proceeds from the sale of shares by the selling shareholders, except for potential proceeds from the exercise of the warrants. The company has also detailed the rights and obligations of ADS holders, including distribution of dividends, voting rights, and fees and charges. The prospectus includes legal considerations such as the enforcement of civil liabilities under UK law and the jurisdiction for legal proceedings. The company has appointed an agent for service of process in the U.S. and has outlined the expenses related to the offering.

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a prospectus with the SEC under Rule 424(b)(3) for the resale of 492,000 ordinary shares represented by 1,230 American Depositary Shares (ADSs). These shares are related to warrants issued during private placements in October 2019 and May 2020, as well as placement agent warrants connected to these placements. The selling shareholders identified in the prospectus may sell the shares at market prices or negotiated transactions. Biodexa Pharmaceuticals will not receive proceeds from the sale of shares by the selling shareholders, except for potential proceeds from the exercise of the warrants. The company has also detailed the rights and obligations of ADS holders, including distribution of dividends, voting rights, and fees and charges. The prospectus includes legal considerations such as the enforcement of civil liabilities under UK law and the jurisdiction for legal proceedings. The company has appointed an agent for service of process in the U.S. and has outlined the expenses related to the offering.